Paris, France / Munich, Germany – July 1, 2016In pursuit of continuing high quality service delivery, ARTTIC has completed its takeover of GABO:mi.
“The GABO:mi people, who are joining us, strengthen ARTTIC’s position as European market leader” said Christian Baumhauer, the President of ARTTIC. “Our combined excellent knowledge and experience will provide us with the means to expand services, deliver deeper support for more proposals and projects. This is great news for our clients and our people. This will allow ARTTIC to further sharpen its strategic focus on providing mission-critical services."
GABO:mi is a German company with a strong track record of successful projects in biological sciences. In addition to the strengthening of ARTTIC’s leadership in consultancy and management services for European research and technology-related partnerships, this take-over also reinforce ARTTIC resources in Germany, especially in the Horizon 2020 fields for health, demographic change and wellbeing.
As part of the takeover, responsibility for supporting 30 projects and 20 employees will be transferred to ARTTIC. In addition, ARTTIC is acquiring :milliarium, a web-based project management tool developed and used by GABO:mi for the management of European projects, especially H2020 and Innovative Medicines Initiative (IMI).
Founded in 2005, GABO:mi gained extensive expertise with diverse EU funding instruments and managed more than 45 medium- and large-scale collaborative projects in FP7, Horizon 2020 and IMI.
GABO:mi was ranked on place 3 among the TOP SMEs in the Final FP7 Monitoring Report in March 2015, being the best German enterprise in this list. Additionally, GABO:mi was certified according to DIN EN ISO 9001 obliging for excellence according to the European Foundation for Quality Management (EFQM).
As ARTTIC, the GABO:mi employees have widespread experience in the management of European projects. The project managers are familiar with the structures of research institutions and with their governing principles. With their expertise and overview they are a perfect partner to shoulder all management and dissemination tasks a successful European project requires.
ARTTIC assists clients from all business and research sectors, small and large, private and public, to ensure the success of their collaborative research & innovation ventures. During close to 30 years of success, ARTTIC developed and demonstrated expertise in the set-up and management of more than 300 large-scale ambitious projects of which 44 already successful under H2020 first calls, Clean Sky calls included. Based on its long-standing experience in a range of funding programmes across scientific and technological domains, ARTTIC helps clients to move from strategic plans to effective competitive research and development of innovative solutions, resulting in successful applications and high-performance businesses.
Founded in Paris in 1987, ARTTIC is now a group of companies with main offices in France (Paris and Toulouse), Germany (Munich and Berlin), Belgium (Brussels), England (Derby) and Israel (Tel Aviv). In 2015, ARTTIC has been ranked first SME in Europe by the European Commission considering the number of grant agreements signed by ARTTIC.
The entire GABO:mi team is very pleased of the start of our new projects, which we have successfully applied for with our partners at the EC:
Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (Small Vessel Diseases, kurz: SVDs) account for more than 30% of strokes and at least 40% of dementia cases. The new research project SVDs@target, coordinated by Prof Dr Martin Dichgans at the Ludwigs-Maximilians-University in Munich will focus on exactly these SVDs and try to elucidate the mechanisms underlying SVDs to develop new therapeutic interventions. SVDs@target is funded with 6m Euro by the EC under the Horizon2020 programme and started on 1 January 2016.
Mental, cognitive, vision and hearing health issues in elderly people are amongst the top 10 public health challenges in Europe. They frequently occur co-concurrently and have an additive negative effect on quality of life and mental well-being. Therefore, the European funded project SENSE-Cog will promote earlier detection of sensory, cognitive and mental impairments to enable swift interventions and prevent deterioration. Coordinated by Dr Iracema Leroi and Dr Piers Dawes, both at the University at Manchester, SENSE-Cog started on 1 January 2016 and is funded with 6m Euro by the EC’s H2020 programme.http://www.sense-cog.eu/
From January 2016 onwards the FOLSMART consortium, consisting of eight partners from four European countries, will continue working on further improvement of treatment possibilities for rheumatoid arthritis (RA). FOLSMART is coordinated by Prof Artur Cavaco-Paulo from the Associacao Universidade empresa para desenvolvimento TecMinho (Portugal). During the predecessor project NANOFOL, the group has successfully developed the therapeutic strategy of the novel treatment method and within the next four years the consortium aims for clinical validation of the therapeutic approach. The start-up FOLMATECH will be established as part of the project and will eventually produce the product and take care of its IP rights and commercialisation.http://www.folsmart.eu
On 1 November 2015, the new H2020 project RELENT has started. RELENT is coordinated by Prof. Dr. Renate Kain from the Medical University in Vienna. The project goal is to develop better therapies for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis. The consortium aims to identify common mechanisms responsible for the persistence and outcomes in these diseases that cause considerable mortality and morbidity. The results should be rapidly translatable into clinical practice for the benefit of patients. RELENT combines the resources of seven leading European research institutions and two from the US and Australia. Three SMEs will supply specific reagents and translate the results to biomarker development. GABO:mi is looking forward to accompany the consortium for the next four and a half years.http://www.relent.eu/
The European Commission has funded a new research project in haemophilia A under its Horizon 2020 programme and GABO:mi is one out of six partners. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy to treat the bleeding disease, haemophilia A (caused by genetic deficiency in clotting factor VIII (FVIII)). The innovative concept of HemAcure consists of the GMP conform isolation, FVIII gene correction and expansion of autologous endothelial cells, which are then transplanted into a proprietary prevascularized GMP manufactured medical device designed for therapeutic cells. The transplanted cells release FVIII into the bloodstream of the patient over an extended period of time, significantly improving the quality of life and reducing the side effects of the disease.
The project, which started on 1 November 2015, will run over three years and is led by Dr. Joris Braspenning of the University Hospital Wuerzburg, Germany.
Diamond should help to produce fuels and chemicals from carbon dioxide and light. This is the goal of a new research consortium receiving around 3.9 million Euro in funding from the European Union. Project start of DIACAT was 1 July 2015. The innovative project is coordinated by Anke Krueger at the University of Würzburg, GABO: mi is responsible for the entire project management.http://www.diacat.eu/
GABO:mi is partner of a new European Research Project which aims at avoiding complications after stroke.
Stroke is the world’s second largest cause of death and the second cause of long-term disability. Elderly patients have a high risk of complications after stroke, such as infections or fever. These complications are strongly associated with a higher risk of death or dependency. The PRECIOUS project will assess whether a pharmacological strategy to prevent the most common complications in elderly patients with acute stroke reduces the risk of death or long-term disability. The project started on 1 June 2015 and runs till June 2020.
Top News! GABO:mi on rank 3 of the TOP 25 SMEs
On rank 3 (rank 4 last year) GABO:mi is the best enterprise in Germany belonging to TOP 25 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest and final FP7 Monitoring Report of the European Commission, published in March 2015.
A strong consortium of 32 EFPIA, academic and SME-partners will collaborate in this project of a duration of 5 years.
The goal of this project is to identify and also treat tumors on the basis of blood-based biomarkers. The focus is on the improvement of available technologies, as well as medication and other treatments, all in all for the well-being of the patient.http://www.cancer-id.eu
1 January 2015 is the day: the project TREGeneration, coordinated by Prof. João Mascarenhas Forjaz Lacerda at the Instituto de Medicina Molecular in Lisbon starts.
TREGeneration has a project duration of 5 years, comprises 8 participants in Portugal, Germany, Belgium, Italy and Great Britain, and is funded with 6 million Euro.
In five parallel clinical trials the effectiveness of donor regulatory T-cells for patients with graft-versus-host disease after hematopoietic stem cell transplantation will be examined.http://www.tregeneration.eu
In a bibliometric analysis of ongoing IMI projects EU-AIMS was rated as the best IMI project on various performance measures.
On scientific output:
1) EU-AIMS has the highest citation impact to date of all IMI projects and 4 times the world average impact.
2) EU-AIMS has the highest percentage of highly cited papers (42% of EU-AIMS publications are in the top decile of publications for journal category and year of publication).
GABO:mi is Project Management Partner of the EU-funded FP7 project DEM-CHILD. The project dealing with research on better diagnose methods and finding ways to slow down NCL disease (batten disease) causing childhood dementia. The project lasted three years and ended in September 2014. For further information on NCL see the video „Laura Story“ “ including explanations of Prof. Jon Cooper (KCL), who was partner in DEM-CHILD.
EPITARGET, a new FP7 Health project, started on 1 November 2013. The consortium is led by the University of Lund with Prof. Merab Kokaia as coordinator and includes members from Sweden, Germany, France, Finland, Italy, United Kingdom, Poland, the Netherlands and Israel. The work will be funded by the EC with nearly 12 million Euros in the course of the next five years.
Epilepsy is a devastating condition affecting over 50 million people worldwide. Current antiepileptic drugs provide only symptomatic relief but cannot cure the condition. This is why EPITARGET is focused on identifying novel biomarkers for epileptogenesis to be able to explore new ways of how to treat epilepsy.
On 1 October 2013, the European Research Project EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) was launched! It is coordinated by Prof. Markus Zabel, University Medicine Göttingen, and it will be funded by the EC with almost 6 million Euros. For the next four years, researchers and physicians of 19 participating institutes located in Europe will analyze the effectiveness of prophylactic implantation of cadioverter defibrillators (ICDs) in Europe.
GABO:mi has supported EU-CERT-ICD during the proposal stage and will be the project management partner for the whole duration of the project.more
The project includes a non-randomised, non-invasive, advanced diagnostics, observational trial in candidates and patients for primary prophylactic ICD therapy. Moreover, a large European registry will be generated collecting available data on prophylactic ICD treatment for comparative analysis. Data from both, the prospective study and the registry will be compared with results from a meta-analysis of existing literature data to estimate QoL-adjusted cost-effectiveness from actual cost comparisons and Markov decision models with attention to sub-groups, regional, and sex comparisons.EU-CERT-ICD is expected to provide important novel information to validate or challenge current guideline indications for primary prophylactic ICD treatment.
On 1 October 2013 the project PRONIA coordinated by Dr. Nikolaos Koutsouleris (Ludwig-Maximilians-Universität München) started its work. The European Commission funds the project with an amount of 6 million Euros.
The project goal is to implement reliable and accessible prognostic tools facilitating the prediction and prevention of psychoses. This objective will be reached by generating a prognostic system based on use routine brain imaging and complementary data.
The long-term aim is also to commercially exploit these prognostic services through internet-based telemedicine applications. This will provide psychosis risk profiling tools to diverse target groups in the healthcare markets, including care-givers, the pharmaceutical industry and research institutions.
The consortium consists of research institutions, SME and industry partners: University of Munich, University of Basel, University of Birmingham, University of Turku, University of Udine, University of Melbourne, as well as Dynamic Evolution, General Electric Global Research and General Electric Healthcare.
GABO:mi supported PRONIA already during the proposal stage and is looking forward to accompanying the consortium throughout the next five years.
CFMATTERS, a new FP7 Health project, started on 1 October 2013. The consortium is led by University College Cork with Dr. Barry Plant as coordinator and includes members from Ireland, the United Kingdom, France, Germany, Belgium and the United States of America. The work will be funded by the EC with nearly 6 million Euros in the course of the next three years.
CFMATTERS is focused on the development and trial of personalized antibiotic treatment for patients with CF during respiratory infections. The treatments will be adapted to the bacteria that cause the infection using next generation DNA-sequencing methods. By implementing a personalized approach for antibiotic prescriptions, ultimately the development of antimicrobial resistances can be limited.http://www.cfmatters.eu
On 1 October 2013 the international European research project CENTER-TBI has started. The project is coordinated by the University of Antwerp, Prof. Andrew Maas, and co-coordinated by the University of Cambridge, Prof. David Menon. The consortium consists of 38 international partners and will run for 6,5 years. The European Commission funds the project with an amount of 30 million Euros.
CENTER-TBI aims to advance the care for patients with traumatic brain injury (TBI), a field in medicine with one of the greatest unmet needs. The research aims to 1) better characterise TBI as a disease, and describe it in a European context and 2) identify the most effective clinical interventions for managing TBI.
FemNAT-CD a new FP7-Health project started on 1 September 2013. Apart from the Goethe University Frankfurt am Main with Prof. Christine Freitag as coordinator, the network includes 16 research institutions and companies from eight EU-states established in Aachen, Amsterdam, Southampton, Basel, Heidelberg, Birmingham, Dublin, Regensburg, Terassa, Bilbao, Szeged, Athens, Munich, Ulm, and Trier. The EU is going to fund the work of the researchers with nearly 6 million Euros over the coming four years.
FemNAT-CD is a multi-center study which deals with paediatric conduct disorders characterized by aggressive traits and/or social impairment with an operating range reaching from preclinical research to treatment.
The key aims of the FemNAT-CD consortium are to identify biomarkers and to study disease mechanisms from pre- to postpubertal female CD (conduct disorder) as well as new psychological and pharmacological treatment options for female adolescent CD targeting emotion processing abilities.
GABO:mi has been already successfully supporting Professor Freitag in the application phase und will accompany the project throughout the whole project duration with professional project management.
On 1 September 2013 the international European research project CULPRIT-SHOCK was started. The project is coordinated by Prof. Dr. Holger Thiele (University of Luebeck, Germany). The European Commission funds CULPRIT-SHOCK for 4 years, with an amount of nearly 6 million Euros.
The CULPRIT-SHOCK study hypothesis is to explore if culprit vessel only PCI with potentially subsequent staged revascularization in comparison to immediate multivessel revascularization by PCI in patients with cardiogenic shock complicating acute myocardial infarction reduces the incidence of 30-day mortality and/or severe renal failure requiring renal replacement therapy.
On 1 September 2013, the project EpimiRNA, coordinated by Prof. David Henshall (Royal College of Surgeons in Ireland) and Prof. Felix Rosenow (Universität Marburg), started its work. The consortium consists of 16 partners from 8 European countries, the USA and Brazil.
Through highly collaborative, inter-disciplinary and inter-sectorial research, EpimiRNA will explain the mechanism by which miRNAs contribute to epileptogenesis, characterize genetic variation of miRNA in patients, evaluate seizure-suppressing effects of miRNAs in experimental models, identify novel miRNA modulatory molecules as potential future therapeutics, and develop miRNAs as prognostic markers to identify patients who respond to novel, non-pharmacological therapeutic interventions including brain stimulation. EpimiRNA will generate the necessary critical mass in biomedical, clinical and industry/SME research to track, treat and prevent seizures and improve the clinical management of epilepsy patients.
GABO:mi supported EpimiRNA during the proposal stage and is looking forward to accompanying the consortium throughout the whole project duration (five years).
On 1 August 2013, the project HypOrth, coordinated by Prof. Christoph H. Lohmann (University of Magdeburg), started its work. The project aims to develop hypoallergenic material for endoprotheses, pursuing two major goals: HypOrth intends to improve the understanding and diagnosis of complications associated with an implant, primarily focussing on adverse immune reaction and infection. Based on these insights the project will develop innovative approaches for renewals in orthopaedic arthroplasty with improved biocompatibility.
The collaboration between research institutions, industry and SME partners is essential for this project. The consortium consists of research institutions based in Germany (University of Magdeburg), Estonia (University of Tartu), Poland (Instytut Obróbki Plastycznej, Metal Forming Institute, Poznan), Hungary (Hungarian Academy of Sciences, Budapest) and Denmark (Danish Technological Institute Centre for Chemistry and Biotechnology, Aarhus), as well as of SME and industry partners from Spain (Progenika, Derio – Vizcaya ) and Switzerland (Mathys AG, Bettlach).
GABO:mi is looking forward to accompanying the consortium throughout the whole project duration (five years).
On 1 May 2013, the new FP7-Health project T-Control started. Funded for three years with nearly 6 Mio Euros by the EC, the five project partners – Universitätsklinikum Würzburg, Anthony Nolan Trust London, Academisch Ziekenhuis Leiden, Stage cell therapeutics GmbH Goettingen, GABO:mi Munich – will develop two new Streptamer-based GMP (good manufacturing practice) compliant cell selection processes and their corresponding cell products. The products are a multivirus and a tumor specific CD8+ T cell product (“multispecific T cell product”), which shall diminish adverse reactions in cell therapies.http://www.t-control.info
In the last HEALTH-Call of the 7th Framework Programme, we were again very successful! The contract negotiations are almost finalized. The scientific coordination of the projects goes to 7 German, 2 Irish,1 Belgian and 1 Swedish institutions:
- Ludwig-Maximilians-University Munich, DE
- University Hospital Wuerzburg, DE
- Johann-Wolfgang-Goethe-University Frankfurt a. M., DE
- Heinrich-Heine-University Duesseldorf, DE
- University Medical Center Goettingen – Georg-August-University Goettingen, DE
- University of Luebeck, DE
- Otto-von-Guericke-University Magdeburg, DE
- University College Cork, Ireland
- Royal College of Surgeons, Ireland
- University Hospital Antwerp, Belgium
- University of Lund, Sweden
Together with our consortium partners, we are looking forward to the Kick-Off-Meetings of these very exciting research projects, in autumn 2013!
HydroZONES - our new research project in the programme nanotechnologies (NMP) - started on the 1 January 2013. Apart from the University Hospital of Würzburg with Prof. Jürgen Groll as coordinator, the network includes research institutions and companies from Heidelberg, Dresden, Aachen, Munich, Oxford, Utrecht, Groningen, Pamplona and the Portuguese city of Leiria. Even an Australian team is involved. The EU is going to fund the work of the researchers with 9.75 million Euros over the coming five years. Healing cartilage defects: This is the objective of the international research network HydroZONES: Bioactivated hierarchical hydrogels as zonal implants for articular cartilage regeneration. Implants that are structured like natural tissue are to provide durable repair of defects in the joint.
GABO:mi has been already successfully supporting Professor Groll in the application phase und will accompany the project throughout the whole project duration with professional project management.
GABO:mi manages its 4th IMI JU project: The European Lead Factory, the largest pan-European drug discovery platform. The 5-year project is coordinated by Bayer HealthCare (Germany). Its funding volume amounts to 196 million Euros. In this project an unprecedented collaboration between industry and academia should pave the way to easily translate findings into treatments for patients and should be the foundation for growth in drug development in Europe.http://www.europeanleadfactory.com
On 1 December 2012 SysmedIBD (Systems medicine of chronic Inflammatory Bowel Disease), a 5-year-project with 12 million Euros EC funding, started its work. Coordinated by Prof. Werner Müller (University of Manchester) the consortium of 12 academic and SME partners focuses on innovative research approaches to chronic inflammatory bowel diseases. http://www.sysmedibd.eu
An international consortium of scientists coordinated by Prof. Graham Thornicroft of the Institute of Psychiatry of King’s College London has launched the EMERALD global mental health project to improve mental health systems in low- and middle-income countries. The objectives of the EMERALD Project are to establish an adequate, fair and sustainable resourcing, integrated provision of physical and mental health and improved coverage of care. EMERALD brings together collaborators from Ethiopia, India, Nepal, Nigeria, South Africa and Uganda.
The project startet on 1 November 2012 and is funded by FP7 for the coming 5 years. GABO:mi has supported Emerald from the proposal stage on and will support and manage the research of the international during the project period.
On rank 4 (rank 14 last year) GABO:mi is the best enterprise in Germany belonging to TOP 25 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest FP7 Monitoring Report of the European Commission, published in August 2012.
Coordinated by Dr. Birgit Köhler, Charité Berlin, the project DSD-Life started on 1 October 2012. The project is funded by FP7 with a lifecycle of 4 years. The project consortium consists of experienced and well-known scientists in the areas of endocrinology, psychology and ethics. Uniting 16 international project partners the project aims for sustainable improvement of clinical and medical care for patients with disorder in sex development (DSD) on European level. http://www.dsd-life.eu
Coordinated by Prof. Franz Schaefer from the Universitätsklinikum Heidelberg, Germany, this FP7 funded 5-year project started its work on 1 October 2012.
EURenOmics unites 19 academic and 8 SME partners from 10 European countries and the US in an international consortium of scientific excellence, bringing together leading clinical, genetic and translational researcher in an unprecedented clinical research network in the field of rare kidney disease.
As the highest ranking proposal of its call, the project was awarded 12 million Euros to study the underlying causes and molecular pathways of several rare and neglected kidney disorders with eminent need and potential for diagnostic and therapeutic progress, using latest “Omics” technologies. Besides the elucidation of fundamental scientific questions, the project will focus strongly on the development of innovative diagnostic tools and biomarkers as well as models for the screening of potential therapeutic agents. This could open the possibility of individualized therapies for the benefit of the more than 30,000 newly diagnosed patients per year suffering from these debilitating kidney diseases. GABO:mi is proud to be a partner in this project and has supported EURenOmics from the proposal stage. http://www.eurenomics.eu
The aim of this ambitious project is to develop a highly-powered and efficient software engine (SENATOR) capable of individually screening the clinical status and pharmacological and non-pharmacological therapy of older people with multimorbidity in order to define optimal drug therapy, highlight ADR risk, indicate best value drug brand for selection and provide advice on appropriate non-pharmacological therapy. 9 Partners under the coordination of Dr. Denis O`Mahony, geriatrician from the University College Cork, Ireland committed themselves for the next 5 years to run the project which started on 1 October 2012 and received 6 million Euros from the European Commission. GABO:mi has supported the consortium starting with the grant application stage and will be responsible for the project management.http://www.senator-project.eu
Coordinated by Prof. Dr. Günter Neumann at the University of Hohenheim (near Stuttgart), the project BIOFECTOR started on 1 September 2012. Having succeeded in a tough competition, BIOFECTOR is funded with 6 million Euros by the European Commission. This project consists of 22 European partners of which 9 partners are small and medium enterprises, actively contributing to the research objective: Improving knowledge on plants and bio-effector interactions with their related physiological and chemical mechanisms. GABO:mi supported BIOFECTOR during proposal stage and is the project management partner during this project of a duration of 5 years.http://www.biofector.info
On 1 July 2012 the international European research project Re-Liver (Bottom-up reconstitution of a biomimetic bioartificial liver) was started, coordinated by Dr. Joris Braspenning (Medicyte GmbH). The long term goal of this European project is to utilize bioartificial liver organoids as alternative to solid organ transplantation. GABO:mi supported the consortium, consisting of five European partners, already in the proposal phase and will take care of the project management during the three-year project duration.
This research project is receiving funding of 4.2 million Euros from the European Commission.
On 1 April 2012, the IMI (Innovative Medicine Initiative) project EU-AIMS started. EU-AIMS is the largest single grant for autism research in the world and the largest for the study of any mental health disorder in Europe which will be led by Dr. Will Spooren (Roche) and Prof. Declan Murphy (King’s College London). EU-AIMS brings together top scientists from 24 academic European institutions and Biotech companies with a wide range of expertise, and partners them with major global drug companies from the European Federation of Pharmaceutical Industry Associations (EFPIA) including Roche, Eli Lilly, Servier, Janssen Pharmaceutica, Pfizer and Vifor Pharma; as well as world leading autism charities including Autism Speaks (USA). The project will study new methods for the development of drugs for autism spectrum disorder (ASD). The research of EU-AIMS will be funded by the IMI, the EFPIA companies and from Autism Speaks over the duration of five years with 29.6 million Euros. http://www.eu-aims.eu
In the last Calls of FP7, we were again very successful. Currently, we are in contract negotiations with 7 projects. Among these, 4 coordinating institutions are located in Germany:
- Universität Hohenheim, D
- Medicyte GmbH (SME) Heidelberg, D
- Universitätsklinikum Heidelberg, D
- Charité Berlin, D
- University of Manchester, UK
- University College Cork, IR
- King‘s College London, IoP, UK
This impressive result is best proof and evidence for a winning team. We are proud of actively supporting the European spirit of research together with our research partners!
On 1 February 2012, the European research project EuroHYP-1 started. The project is a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke and is coordinated by Prof. Stefan Schwab at the Universitätsklinikum Erlangen, Germany. The project includes 35 European partners and one international partner organization from Australia. It will be funded by the European Commission over the duration of five years with 10.9 million Euros. GABO:mi has successfully supported EuroHYP-1 from the proposal phase on.
Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so its social and economic burden will grow with the ageing of the European population. Systematic review of experimental studies suggests that hypothermia is the most promising intervention identified to date. Therapeutic cooling is effective in reducing ischaemic brain injury following cardiac arrest, and hypothermia is therefore considered by experts the most promising treatment for patients with acute ischaemic stroke, next to reperfusion strategies.
The EuroHYP-1 trial is a pan-European, open, randomised, phase III clinical trial which will assess the benefit or harm of therapeutic cooling in 1500 awake adult patients with acute ischaemic stroke. The investigators involved in the EuroHYP-1 consortium are leading European experts in statistical design and analysis, therapeutic hypothermia, imaging, health economics, ultrasound, biomarkers, and trial execution (implementation and monitoring); furthermore, the consortium involves European patient and family advocacy groups and small and medium-size enterprises, in order to ensure the successful enrolment of patients and the data analysis.
On 1 January 2012 the European research project DORIAN (Developmental Origins of healthy and unhealthy Ageing: the role of maternal obesity) was started, coordinated by the Institute of Clinical Physiology-CNR, Consiglio Nazionale delle Ricerche in Pisa, Italy. Dr. Patricia Iozzo and her team were successfully supported by GABO:mi from the proposal stage onwards. The European Commission funds DORIAN for 3 years, with an amount of 3 million Euros.
This multidisciplinary project will generate a better understanding of the basic mechanisms of early life development and ageing, which may translate into the improvement of health and quality of life during the entire life course. In particular, the Consortium of DORIAN will investigate and analyze the impacts of maternal obesity on the way of ageing and its associated degenerative pathologies in the offspring through the duration of life.http://www.dorian-fp7.eu
On 1 January 2012 the European research project EUROFORGEN-NoE (European Forensic Genetics Network of Excellence) started. The project is led and coordinated by the University of Cologne/Institute of Legal Medicine, Prof. Peter Schneider. Its consortium consists of 12 European partners and involves outstanding and well-known scientists within the field of forensic genetics, aiming for the initiation of a sustainable Network of Excellence. GABO:mi supported the consortium successfully during the proposal phase. The project will run for 5 years and is funded by the European Commission with an amount of 6.6 million Euros.http://www.euroforgen.eu
On 1 January 2012 the international European research project NILVAD (A European multicentre double-blind placebo-controlled phase III trial of nilvadipine in mild to moderate Alzheimer’s disease) started, coordinated by the Trinity College Dublin (TCD), Ireland. Prof. Brian Lawlor and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds NILVAD for 5 years, with an amount of 6 million Euros. more
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).
There is therefore an imperative to develop new treatments for AD that have disease modifying effects. NILVAD performs a double-blind placebo controlled study that will test the efficacy and safety of nilvadipine in 500 subjects with mild to moderate AD over a treatment period of 18 months. Male and female patients with mild to moderate AD aged between 50 and 90 with a range of medical morbidities and frailty will be included in the study. If this trial is successful, nilvadipine would represent an advance in the treatment of AD patients and would have a major impact on the health and social care costs incurred in Europe by this neurodegenerative disorder.
On 1 January 2012 the international European research project DITAC (Disaster Training Curriculum) started, coordinated by the Universitaetsklinikum Bonn. Dr. Philipp Fischer and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds DITAC for 3 years, with an amount of 4 million Euros.more
A European multi-disciplinary team of experts is collaborating to develop a standardised curriculum for international crises management hereby referred to as DITAC. The DITAC project aims to develop a holistic and highly structured curriculum for first responders and strategic crisis managers that are tasked in dealing with disasters on a national and international scale. The curriculum will tackle dynamic challenges facing disaster incident managers in order to enhance the efficiency, efficacy, coordination, coherence and appropriateness of their response efforts. These skills are crucial because of an alarming increase in the frequency, intensity and complexity of disasters while governments are simultaneously facing budgetary constraints on humanitarian aid due to overwhelming sovereign debt. less
The European research project WAKE-UP (Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial) started on 1 December 2011. The project is coordinated by the University Medical Center Hamburg-Eppendorf, Prof. Christian Gerloff. GABO:mi already supported the consortium successfully during the proposal phase. The consortium consist of 13 European partners and will run for 5 years. The European Commission funds the project with an amount of 12 million Euros.more
The objective of the research proposed in the WAKE-UP project is to provide expanded treatment options for acute stroke improving the outcome of stroke patients, thus reducing the burden of stroke. For this purpose, WAKE-UP will conduct an investigator-initiated multicentre randomised double-blind placebo-controlled trial designed to test efficacy and safety of magnetic resonance imaging (MRI)-based intravenous thrombolysis in patients waking up with stroke symptoms or patients with unknown symptom onset.http://www.wakeup-stroke.eu
On 1 November 2011, the European research project EpiPGX (Epilepsy Pharmacogenomics: delivering biomarkers for clinical use) started, coordinated by the University College London. Professor Sanjay Sisodiya and his team were already successfully supported by GABO:mi during the proposal stage. The European Commission funds EpiPGX for 4 years, with an amount of 6 million Euros.more
The purpose of EpiPGX is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs). The project will use genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current antiepileptic drugs (AEDs) and identify new therapy targets. SMEs, which are central to this project, will be able to take the data forward for development of clinical tests.http://www.epipgx.eu
On 1 October 2011, the research project DEM-CHILD (A Treatment-Oriented Research Project of NCL Disorders as a Major Cause of Dementia in Childhood) started. The consortium is led by Dr Angela Schulz, University-Clinic Hamburg-Eppendorf and consists of 10 international partners. The outstanding aspect of this project is the collaboration with a partner in India where dementia in childhood is as critical an issue as in Europe. GABO:mi supported the consortium successfully during the proposal phase, and is now an active partner taking care of all project management tasks. The project duration is 3 years and the funding by the European Commission amounts to 3 million Euros. http://www.dem-child.eu
The FP7 project EuroSkinGraft started on 1 October 2011 and is coordinated by the University Zurich. The project deals with a novel generation of skin substitutes to clinically treat broad spectrum of severe skin defects. GABO:mi is the project management partner, who has successfully accompanied the consortium through the proposal phase. The consortium consists of 7 European partners and is funded for 5 years with an amount of 6 million Euros by the European Commission.
Report on skin grafting on Swiss TV TV broadcast
Together with some researchers of the project CARDIORISK, we managed to win a grant for a follow-up project. The project ProCardio deals with cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation. ProCardio is coordinated by Prof. Michael J. Atkinson, Helmholtz Zentrum for Environmental Health Munich. The project is due to start on 1 October 2011. For a period of three years, we support the researchers in project management and the development of a website.http://www.procardio.eu
GABO:mi belongs to TOP 20 SMEs
On position 14 GABO:mi is the only enterprise in Germany belonging to TOP 20 SMEs (Small and Medium Enterprises) in Europe. This information is part of the latest FP7 Monitoring Report of the European Commission, published in August 2011.
In the last Calls of FP7, we were very successful. Currently, we are in contract negotiations with 11 projects. Among these, 6 coordinating institutions are located in Germany:
- Universitätsklinikum Hamburg-Eppendorf, D (two projects)
- Klinikum der Universität zu Köln, D
- Universitätsklinikum Bonn, D
- Helmholtz Zentrum München, D
- Universitätsklinikum Erlangen, D
- University College London, UK
- King‘s College London, IoP, UK
- Trinity College Dublin, IR
- Universität Zürich, CH
- Consiglio Nazionale delle Ricerche, Pisa, I
This impressive result is best proof and evidence for a winning team. In twofold dimension: on the one hand, a successful team together with the researchers and on the other hand, a committed project management team. We are proud of actively supporting the European Idea and spirit of research!
Four of these eleven projects have already carried out successful PR work:
- Trinity College Dublin: "Clinical Trials for New Alzheimer's Disease Treatment to be Awarded European Commission €6 million Funding"
press release Alzheimer Research Forum
- Universität Zürich: Report on skin grafting (Project EuroSkinGraft) on Swiss TV TV broadcast
- Universitätsklinikum Hamburg-Eppendorf: Report on stroke (Project Wake-up) on German TV TV broadcast
- Universitätsklinikum Erlangen: Report on hypothermia (Project EuroHyp) on German TV TV broadcast
PREDI-NU – Continuation of a success story
Together with the researchers of the project EAAD (European Alliance Against Depression), we managed to win a grant for a follow-up project. The project PREDI-NU (Preventing Depression and Improving Awareness through Networking in the EU) deals with the improvement of education and the prevention of depressions. The main objective is the development of an Internet-based self-management platform for young people with mild depressions. The project is due to start on 1 September 2011. For a period of three years, we support the researchers in project management, development of a website and an IT-platform.
On 1 January 2011, our second IMI JU – project (Innovative Medicines Initiative) OncoTrack, led by Dr David Henderson, Bayer Schering Pharma AG and Prof. Hans Lehrach, Max-Planck Institute for Molecular Genetics started. Over the next five years, in total 18 renowned universities, biotech companies and European pharmaceutical companies join forces for the research of biomarkers in the field of cancers, in order to better adjust therapies for the patient.
Coordinated by Dr. Sascha Sauer of the Max-Planck-Institute for Molecular Genetics, ESGI (European Sequencing and Genotyping Infrastructure) will develop a European infrastructure for DNA sequencing and genotyping. ESGI will provide access to top-notch DNA-sequencing establishments, with a total budget of 10 million Euros.
Over the last 30 years, there was massive progress in the field of biomedical research. At the same time, costs dropped dramatically. The quality of sequencing methods was increased. In the meantime, genomes can be examined entirely and molecular networks can be analysed efficiently. ESGI will support Europe in becoming the leading region in genetic research. For more information: www.esgi-infrastructure.eu
In the course of the next 5 years, ENS@T-CANCER (European Network for the Study of Adrenal Tumours – Structuring clinical research on adrenal cancers in adults) takes care of research on adrenal gland cancer. This type of cancer is a rare cancer with very poor prognosis. The diagnosis usually happens that late, that tumour cells have already started settling on neighbouring organs. The European Commission funds this project with an amount of 6 million Euros.more
In the next 5 years, the ENS@T-CANCER consortium will develop new methods for the diagnosis and treatment of adrenal cancer. At the same time, a network of treatment centres is to be established via ENS@T-CANCER, in order to provide the most current and modern methods to the patients. It is the international cooperation that enables the research on such types of rare cancer.
The scientific coordinator of this project is Prof. Felix Beuschlein, of the Ludwigs-Maximilian-Universität (LMU) in Munich. Besides GABO:mi as project management partner, there are another 13 partners in this project.
On 1 November 2010, the international European research project INTRICATE (Infection triggers of chronic autoimmunity) started, coordinated by the Medical University Vienna. Prof Dr Kain and her team were already successfully supported by GABO:mi through the proposal phase. The European Commission funds INTRICATE for four years, with an amount of 6 million Euros.more
INTRICATE is a unique project which brings together renowned scientists from various academic institutions and SME's, of whole Europe and the USA. The project should find out the links between infections and autoimmune diseases. INTRICATE examines the connection between specific infections and the autoimmune disease "Systemic Vasculitis", which is characterized by an inflammatory destruction of the blood cells, arteries and veins. The results of INTRICATE should then be translated into clinical applications. That way, it will be possible to make predictions and to carry out monitoring of the inflammatory processes which trigger Systemic Vasculitis.http://www.intricate.eu
The FP7 project “The HIP Trial" started on 1 October 2010 and is coordinated by the University College Cork in Ireland. GABO:mi is the project management partner, who has successfully accompanied the consortium through the proposal phase. The consortium consists of 13 European and Canadian partners and is funded for 5 years with an amount of 5,7 million Euros by the European Commission.more
HIP (Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn) is a clinical trial, in which better therapies for preterm births are developed. According to conservative studies, about half of all preterm births suffer from too low blood pressure. This condition often leads to brain damage, disturbance of the neuronal development with a livelong disability as a consequence and is further associated with an increased mortality. It is the aim of the study to develop efficient medicines, which do not only increase the babies' chances of survival, but also protects them from long-term disabilities. less
Copyright © by GABO:mi mbH & Co. KG, e-mail: dialog(at)gabo-mi.com